Article

Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells.

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Transfusion (Impact Factor: 3.57). 07/2006; 46(6):885-8. DOI: 10.1111/j.1537-2995.2006.00819.x
Source: PubMed

ABSTRACT Transfusion-associated graft-versus-host disease (TAGVHD) is a lethal complication of transfusion of nonirradiated cellular blood components to a susceptible recipient.
An 82-year-old man underwent cardiac surgery during which he received 6 units of red cells (RBCs) and a 6-unit pool of platelets (PLTs). He was discharged with a normal white blood cell (WBC) count and hemoglobin (Hb) level and a PLT count of 104x10(9) per L. He was readmitted 2 weeks later with a diffuse erythematous rash, a sore throat, and difficulty swallowing. His WBC count was 2.1x10(9) per L, his Hb level was 12.0 g per dL, and his PLT count was 131x10(9) per L. The next day he had worsening cytopenias: WBC count, 1x10(9) per L; Hb level, 10.9 g per dL; PLT count, 104x10(9) per L. He also had diarrhea. A marrow biopsy showed a severe hypoplasia without evidence of malignancy. A skin biopsy showed Grade II GVHD. The patient worsened and despite aggressive therapy he expired on Postoperative Day 42. DNA-based HLA testing of the 12 blood donors was performed. One of the RBC donors was found to be homozygous for an HLA Class I and Class II haplotype in the patient.
This is the first reported case in the United States of fatal TAGVHD from RBCs in an immunocompetent patient who received a randomly selected unit of RBCs from a donor who was homozygous for a shared HLA haplotype. The policy of selective irradiation should be reexamined.

1 Follower
 · 
62 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Accumulated evidence demonstrates that allogeneic blood transfusions have clinically significant effects on the recipient's immune system. This transfusion immunomodulation effect is associated with an increased rate of cancer recurrence (uncertain causality) and post-operative infection (established causality). The exact mechanisms of transfusion immunomodulation are still unknown. Data suggests that transfusion immunomodulation is a biologic effect strongly associated with the infusion of allogeneic leukocytes. Soluble mediators that accumulate in transfused red cells and platelets during storage are also possible causes of post-transfusion complications. Some approaches can mitigate these effects. Most important is adopting more conservative transfusion practices. Leukoreduction (proven) and plasma depletion (proposed) are other methods to significantly reduce transfusion immunomodulation and its clinical sequela.
    Expert Review of Hematology 10/2013; DOI:10.1586/17474086.2013.850026 · 2.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The acute blood transfusion reactions are responsible for causing most serious adverse events. Awareness about various clinical features of acute and delayed transfusion reactions with an ability to assess the serious reactions on time can lead to a better prognosis. Evidence-based medicine has changed today's scenario of clinical practice to decrease adverse transfusion reactions. New evidence-based algorithms of transfusion and improved haemovigilance lead to avoidance of unnecessary transfusions perioperatively. The recognition of adverse events under anaesthesia is always challenging. The unnecessary blood transfusions can be avoided with better blood conservation techniques during surgery and with anaesthesia techniques that reduce blood loss. Better and newer blood screening methods have decreased the infectious complications to almost negligible levels. With universal leukoreduction of red blood cells (RBCs), selection of potential donors such as use of male donors only plasma and restriction of RBC storage, most of the non-infectious complications can be avoided.
    Indian journal of anaesthesia 09/2014; 58(5):543-51. DOI:10.4103/0019-5049.144650
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been suggested for more than forty years that blood and blood components be irradiated before allogeneic transfusions for immunosuppressed patients in order to avoid the Transfusion-Associated Graft-versus-Host Disease (TA-GVHD). Whole blood, red blood cells, platelets and granulocytes may have viable T cells and should be irradiated before transfusion for different patient clinical conditions. According to international guides, absorbed doses from 25 up to 50 Gy should be delivered to the central middle plane of each blood bag. Although gamma and X-rays from radiotherapy equipments and dedicated cell irradiators are commonly used for this purpose, electron beams from Linear Accelerators (LINACs) could be used as well. In this work, we developed a methodology able to acquire dosimetric data from blood irradiations, especially after fast electrons exposures. This was achieved using a proposed Fricke Xylenol Gel (FXGp) dosimeter, which presents closer radiological characteristics (attenuation coefficients and stopping-powers) to the whole blood, as well as complete absorbed dose range linearity. The developed methodology and the FXGp dosimeter were also able to provide isodose curves and field profiles for the irradiated samples.
    Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms 12/2014; 341:65-71. DOI:10.1016/j.nimb.2014.09.008 · 1.19 Impact Factor